Wearable system for changing mechanical properties and structures in the eye

Abstract

A wearable system and method for changing properties of an eye are provided. The system includes an ultrasound device; at least one sealed cavity; a fluid and illumination environment control device; a controller; one or more feedback sensors; and a computing device. The method includes applying vibrations by an actuator in contact with the orbital bone via the skin; heating the cavity to set a temperature to a first temperature for a period of up to a predetermined time until the temperature exceeds a second temperature; upon reaching the set temperature, setting a vibration cycle; after reaching the set temperature and after completing the set vibration cycle, starting a cavity pressure cycle; completing the cavity pressure cycle and then completing the heating. The system and method can be applied to surgical treatment, medication, finger massage, or independently to change tissue properties of the eye.

Description

[0001] Cross-reference to related applications This application claims the benefit of U.S. Provisional Application No. 63 / 632,525, filed April 11, 2024, which is incorporated herein by reference in its entirety (including any figures, tables, or drawings). Summary of the Invention

[0002] Embodiments of the present invention relate to wearable systems and methods for altering the mechanical properties and structures of the eye.

[0003] According to an embodiment of the present invention, a wearable system for altering the characteristics of the eye is provided. The system includes: an ultrasound device; at least one sealed cavity; a fluid and lighting environment control device; a controller; one or more feedback sensors; and a computing device. The fluid and lighting environment control device is configured to control a liquid or gas. The ultrasound device is configured to contact the skin around the eye socket. Furthermore, the ultrasound device is configured to apply ultrasound waves to the eye socket and to connective tissue connected to the eye socket. The fluid and lighting environment control device is configured to sense and control fluid characteristics and lighting characteristics. The fluid characteristics are the gauge pressure, temperature, humidity, or chemical concentration of the fluid in the cavity. Furthermore, the ultrasound device and the fluid and lighting environment control device are connected to the computing device to form a sense-control-feedback unit to maintain a variable environment. The fluid characteristics and the lighting characteristics, as well as the structures in fluid and lighting communication with the wearable cavity, are determined and adjusted by the computing device or by a user. The structures in fluid and lighting communication with the wearable cavity include the eyeball, a channel connecting the interior of the eye to the surface of the eye, and channels on the eyelids for delivering fluid and lighting to the cavity.

[0004] In another embodiment of the invention, a method for altering the characteristics of the eye is provided. The method includes: applying vibration via an actuator that contacts the orbital bone through the skin; heating a cavity to set a temperature to a first temperature for a predetermined time period until the temperature exceeds a second temperature; setting a vibration cycle after reaching the set temperature; initiating a cavity pressure cycle after reaching the set temperature and after completing the set vibration cycle; completing the cavity pressure cycle, and then completing the heating. The first temperature is 40°C, the predetermined time is 30 minutes, and the second temperature is 42°C. The actuator is configured to vibrate in the range of 0.5 MHz to 4 MHz. Furthermore, the vibration is configured to surround the orbit, enabling the relaxation of appendages and tissues attached to the orbit. The cavity pressure cycle is performed in the range of 500 mmHg to 900 mmHg and for a period of up to 30 minutes. The cavity pressure cycle includes a starting cycle, a changing cycle, and an ending cycle. Specifically, the initial cycle includes a pressure-holding cycle with increments of at least 5 mmHg and a duration of at most 1 minute to set the initial pressure in the dilation cycle. The changing cycle includes at least five negative pressure-holding cycles with or without leakage, each with increments of at least 5 mmHg and a duration of at most 10 minutes. The changing cycle includes at least five negative and positive pressure-holding cycles with increments of at least 5 mmHg and a duration of at most 10 minutes, each with leakage. The ending cycle includes a pressure-holding cycle with increments of at least 5 mmHg and a duration of at most 1 minute to set the negative pressure to 2 mmHg lower than the external pressure. Attached Figure Description

[0005] Figure 1 This is a schematic diagram of a blocked meibomian gland according to an embodiment of the present invention.

[0006] Figure 2 This is a schematic diagram of fluid transport in the Schlemm's canal during intraocular pressure equilibration according to an embodiment of the present invention.

[0007] Figure 3 The mechanical behavior of a viscoelastic organization without relaxation according to an embodiment of the present invention is shown.

[0008] Figure 4 The mechanical behavior of a viscoelastic tissue under relaxation conditions and the dilation of Schlemm's canal after relaxation are illustrated according to an embodiment of the invention.

[0009] Figure 5 The changes in tear production under relaxed conditions are illustrated according to an embodiment of the present invention.

[0010] Figure 6 The continuous tear production under daily wear conditions according to an embodiment of the present invention is illustrated.

[0011] Figure 7 This illustrates a sustained reduction in intraocular pressure after continuous wear, according to an embodiment of the present invention.

[0012] Figure 8 This is a schematic diagram illustrating the change in eyeball shape as a function of the change in the fluid environment within the sealed cavity surrounding the eye, according to an embodiment of the present invention. Detailed Implementation

[0013] Embodiments of the present invention relate to wearable systems and methods for altering the characteristics of the eye.

[0014] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the invention. As used herein, the term "and / or" includes any and all combinations of one or more of the associated listed items. As used herein, the singular forms "a (and an)" and "the" are intended to include both the plural and singular forms unless the context clearly indicates otherwise. It will also be understood that the terms "comprises and / or comprising," when used in this specification, specify the presence of the stated features, steps, operations, elements, and / or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and / or groups thereof.

[0015] Unless otherwise defined, all terms used herein (including technical and scientific terms) shall have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. It will also be understood that terms such as those defined in common dictionaries shall be interpreted as having the same meaning as they have in the relevant field and in the context of this disclosure, and shall not be interpreted in an idealized or overly formal sense unless expressly defined herein.

[0016] When the term “about” is used in conjunction with a numerical value in this document, it should be understood that the value may be in the range of 90% to 110% of the value, that is, the value may be + / - 10% of the value. For example, “about 1 kg” means 0.90 kg to 1.1 kg.

[0017] According to embodiments of the present invention, a wearable system and method are provided for altering the characteristics of one or both eyes of a patient. The system and method can modify the biomechanical properties of the eye and the structural shape of features within the eye.

[0018] In one embodiment, the wearable system includes an ultrasound device, at least one sealed cavity, a fluid and lighting environment control device, a controller, one or more feedback sensors, and a computing device, wherein the fluid may include liquids and gases. Specifically, the ultrasound device is configured to contact the skin around the eye socket to apply ultrasound waves to the eye socket and the connective tissue connected to it. The environment control device is configured to sense and control fluid and lighting characteristics, including, but not limited to, the fluid gauge pressure, temperature, humidity, and chemical concentration of the fluid within the cavity. The ultrasound device and the environment control device are connected to the computing device and a wireless module to form a sense-control-feedback wearable unit to maintain a variable environment. Variable gauge pressure and variable eye temperature in structures fluidly connected to the cavity are determined by the computing device or the user and communicated via the wireless module. Structures fluidly and lightly connected to the wearable cavity can be adjusted, including the eyeball, channels connecting the interior of the eye to the surface of the eye, and channels on the eyelids for delivering fluid and lighting to the wearable cavity. Controlling the cavity environment of the eye and controlling ultrasound vibrations on the eye can drive desired changes in the relaxation and biomechanical properties of structures fluidly and lightly connected to the cavity. By being used repeatedly, wearables can drive and maintain desired changes in the size and shape of the eyeball and the size and shape of the channel during and after repeated wear.

[0019] According to embodiments of the invention, the biomechanical properties of the eye can be modulated, allowing for relaxation of tissues and changes in the shape and size of features within the eye. When tissues relax, the size and shape of the pressure channels expand. Continued relaxation of the eye's biomechanical properties leads to structural changes in the channels within the eye.

[0020] Furthermore, the pressure loading mode that minimizes negative closure effects is superior to the loading mode that causes channel closure. Once the load is removed, the structural changes induced by the load recover elastically and rapidly. Increasing the viscous component slows down the recovery, thereby prolonging the expansion between wear cycles. The viscous properties of tissues in the eye can be enhanced through chemical treatments, drugs, or temperature increases, thereby promoting increased and sustained expansion until the next wear session, such as... Figure 3 As shown.

[0021] The cornea and sclera consist of viscoelastic collagen and fibrin. The mechanical behavior of viscoelastic materials is time-dependent, distinguishing it from that of time-independent elastic materials. When a load is applied to a viscoelastic structure, the immediate and residual displacements after the load is removed depend on the time-dependent relaxation behavior of the viscoelastic material, as well as on the load, loading rate, or loading mode.

[0022] Wearable devices that relax the tissue around the fluid channel facilitate the maintenance of displacement and channel expansion after the load is removed. Applying a gauge pressure load to the channel helps drive its opening. When worn periodically, the elasticity of the corneal and scleral tissue around the Schlem's canals is relaxed, and the viscous component is enhanced, thereby inhibiting expansion and displacement recovery. Relaxed structures with lower elasticity expand more upon relaxation. The gap between the initial opening size and the expanded state can be further increased by adding a gauge pressure load during or after heating and vibration. An incubation period is required before the tissue is fully relaxed. Once the tissue is fully relaxed after the incubation period, the viscoelastic properties do not immediately return to their initial state. During the post-incubation period, expansion recovers slowly due to higher damping and lower elasticity. After the incubation period, enhanced expansion is achieved, i.e., a high canal cross-sectional area (CSA). Figure 4 As shown, post-incubation expansion can be maintained using conventional wearable devices.

[0023] Fluid flow

[0024] Lacrimal puncta: These are small openings in the inner corners of the upper and lower eyelids. Tears flow into the lacrimal canaliculi (tiny channels on the inner eyelid). From there, the tears travel into the lacrimal sac. Blinking, caused by increased surface pressure, balances the fluid pressure on the eye's surface with the pressure inside the sac, driving fluid drainage, mixing with meibum, and coating the eye.

[0025] The meibomian glands on the edge of the eyelid play a crucial role in maintaining eye health. These tiny glands produce an oily substance called meibum, which combines with other fluids to form tears. The meibomian gland pores are where meibum is released onto the eyelid margin. Figure 1 The balance of surface pressure, internal pressure in the meibomian glands, and fluid pressure on the surface of the eye drive fluid drainage.

[0026] The ciliary body produces aqueous humor and secretes the fluid into the posterior chamber. Most of the aqueous humor leaves the eye at the angle formed by the junction of the iris and cornea. A small amount of aqueous humor drains through the ciliary body surface. It enters the uveal-scleral pathway, which involves the ciliary muscle as well as the supraciliary body and suprachoroidal space. Most of the aqueous humor enters the trabecular meshwork and flows into Schlem's canals at the corneal-scleral junction, eventually exiting the eye. Fluid drainage is driven by the balance of surface pressure, the fluid pressure within the canals, and the fluid pressure on the surface of the eye. The lacrimal glands produce tears.

[0027] Meibomian glands are located on the eyelids. Devices such as Lipidflow clamp the eyelids and squeeze the glands from both sides for 10 to 15 minutes to relax and remove clots. Clinicians use anesthetics during the procedure to alleviate discomfort.

[0028] Fluid drainage channels in the eye (including such as Figure 2 The Schlemne canals, lacrimal sac, suprachoroidal space, and meibomian glands (shown in the diagram) are in fluid communication with the surface of the eye. Only the outer surface of the eyeball is accessible to the outside. Bilateral compression of the Schlemne canals, lacrimal sac, and suprachoroidal space is impossible without invasive procedures. The body relies on gauge pressure to expel fluid to the outside, which includes the internal pressure within the canals and the fluid pressure on the surface of the eye. Systems that affect changes in fluid pressure on the surface of the eye can alter the gauge pressure within the canals and the eyeball.

[0029] In addition, one method to alter fluid pressure changes in the eye is to place the head inside the pressure-controlled chamber of a helmet. Theoretically, reducing the pressure within the helmet cavity would increase gauge pressure. Tests using this method showed that the gauge pressure of aqueous humor drainage, or intraocular pressure, remained unchanged and was unrelated to the pressure within the sealed helmet.

[0030] Instead of changing gauge pressure, a method was provided to open the Schlem's canals through direct contact. Unilateral circular finger massage movements through the eyelid were tested on the Schlem's canal region. Imaging showed that the Schlem's canals were temporarily open in some cases and closed in others. Channel closure was a negative side effect. Effects such as asymmetric loading from the skin side showed difficulty in controlling the results and suppressing the negative side effects.

[0031] The tubules and eyeball are composed of viscoelastic materials. The cross-sectional area (CSA) of Schlem's tubules decreases with age. This decrease is associated with tissue stiffening, which is age-related. Relaxing the tissue can help increase CSA. Plasticity can be temporarily increased by warming the eye, and the channels can be dilated by temporarily increasing gauge pressure. When the gauge pressure load is removed after heating, the changes caused by softening and gauge pressure application disappear.

[0032] Materials and methods

[0033] Figure 5 This demonstrates the effect on persistent tearing, while Figure 6 The effect of meibomian fat production is shown. Tears production is enhanced after wearing, and this enhancement is effective for one hour after wearing, indicating that the relaxation dilation persists after wearing. Figure 6The tear destruction time shown indicates that tears stabilize through meibomian fat, and meibomian fat production increases after daily use. Results show that an incubation period of 3 to 14 days is required before reaching steady-state mechanical properties in the channel tissue. Increased tear production and a longer TBUT are indicators of increased meibomian fat production. These results confirm that channel dilation can be maintained when the tissue surrounding these channels relaxes due to regular wear of the wearable device after incubation.

[0034] Figure 7 The effect on aqueous humor drainage is shown. When drainage improves immediately, sustained improvement, as indicated by a decrease in intraocular pressure, is observed after an incubation period of up to 8 weeks. Older adults with age-related sclerosis may respond more quickly than younger, healthy adults. Figure 7 As shown, the decrease in IOP indicates that an incubation period is necessary, and that conventional wearable devices are effective in maintaining the expansion of the channels that transport aqueous humor from the eye to the outside.

[0035] The systems and methods of this invention can be applied to surgical treatments, pharmaceuticals, finger massage, or independently to alter the tissue properties of the eye. The systems and methods can be implemented using variations of wearable devices designed to fit over one or both of a user's eyes, and mechanisms that alter the environment, including hydrostatic pressure within one or more cavities of the wearable.

[0036] Furthermore, the outer surface of the wearable can seal against the skin around the periphery of the patient's eye socket. When a system that periodically alters the environment is activated, environmental changes can be generated and maintained within the wearable cavity, including periodic gauge pressure and temperature and chemical concentration differences from the external environment. This circulatory cavity environment alters the structural and mechanical properties of the eye. These properties can be relaxed and softened by increasing the chemical concentration of tissue-relaxing drugs to relax tissues, and by increasing the eye's temperature through radiation from a radiant heat source and thermal conduction through the heat source. The circulatory gauge pressure difference is applied simultaneously with the chemical and thermal distribution, or after softening, to relax and dilate the eye's structures.

[0037] The warmth, vibration, and medicated mist within the cavity of the wearable device relax and soften the eye, increasing its plasticity. Periodic gauge pressure within the cavity allows the relaxed, plastic eye tissues to expand and contract.

[0038] According to embodiments of the present invention, a wearable method system based on a low-dose relaxation approach is provided to alter the properties of the eye. The method and system integrate vacuum, heat, and light, utilizing low-power OLED technology to provide a gentle, ultra-safe method for eye health and relaxation. The method and system offer several benefits, including increased choroidal thickness, which supports improved blood flow and oxygen supply to the retina and potentially stabilizes axial elongation. The therapy also promotes better ocular blood circulation, helping to maintain overall eye health while reducing the risk of myopia complications. Furthermore, it effectively relieves eye fatigue and strain by relaxing the ciliary muscle, making it particularly suitable for people who engage in prolonged close-up work or use digital screens. Designed with safety as a priority, the therapy employs an ultra-low-power design to ensure minimal risk while providing optimal relaxation benefits.

[0039] The method and system are based on a low-power OLED light source that emits mixed red light in the wavelength range between 600 nm and 700 nm. Power output is maintained within a safe and controllable range of 0.030 mW to 0.06 mW, ensuring a gentle yet effective therapeutic effect. To enhance the uniformity and intensity of the emitted light, the system can be further combined with a dynamic light diffuser, which can be used with or without a polarizer. When a polarizer is applied, it helps reduce glare and ensures a more uniform light distribution. Without a polarizer, the light is more widely distributed, adapting to different therapeutic needs.

[0040] Each treatment session lasts approximately 30 minutes, allowing sufficient time for the light exposure to take effect. Treatments can be administered twice a day, with a mandatory interval of at least four hours between treatments to prevent overstimulation. Treatment follows a structured schedule, requiring five treatments per week for optimal results.

[0041] The methods and systems are carefully designed to maintain a low and safe energy dose. The total energy delivered during each treatment session depends on the power setting. For example, at 0.03 mW, the energy dose reaches 54 millijoules over a 30-minute (1800-second) session. At 0.06 mW, the dose increases to 108 millijoules over the same duration. These energy levels are intentionally kept low to ensure maximum safety and comfort while still providing effective relaxation and eye health benefits.

[0042] By combining precise light modulation with controlled exposure, the method and system provide a non-invasive, safe, and efficient way to reduce eye fatigue, improve ocular circulation, and support long-term eye health.

[0043] In some embodiments, the system for controlling and altering the cavity environment pressure within the wearable cavity may be a computer-controlled pump with a computer-controlled air valve and a pressure sensor. The eye temperature system may consist of a temperature sensor and a heating subsystem, wherein the subsystem may be a radiant heating or conductive heating system. The chemical dispensing system may be a chemical that evaporates upon heating and is immersed in a porous medium, or a spray subsystem that fills the cavity with a mist, along with a camera for monitoring eye conditions, including eye movement and displacement over time.

[0044] In some embodiments, the system's power source may be a rechargeable battery or another battery integrated into one or more wearables. The system may be manually actuated or configured to follow a cyclic profile specified by a program in the wearable computer.

[0045] Example 1. A wearable system for altering the properties of the eye, comprising: Ultrasonic equipment; At least one sealed cavity; Fluid and lighting environment control equipment; Controller; One or more feedback sensors; and Computing devices.

[0046] Example 2. The system according to Example 1, wherein the fluid and lighting environment control device is configured to control lighting, liquid or gas.

[0047] Example 3. The system according to Example 1 or 2, wherein the ultrasound device is configured to contact the skin around the eye socket.

[0048] Example 4. A system according to any of the foregoing embodiments, wherein the ultrasound device is configured to apply ultrasound waves to the orbit and to the connective tissue connected to the orbit.

[0049] Example 5. A system according to any of the foregoing embodiments, wherein the fluid and lighting environment control device is configured to sense and control at least one fluid characteristic and at least one lighting characteristic.

[0050] Example 6. The system according to Example 5, wherein the fluid characteristic is at least one of the fluid gauge pressure, temperature, humidity or chemical concentration of the fluid in the cavity.

[0051] Example 7. The system according to Example 6, wherein the controlled fluid and lighting characteristics include illuminance of the fluid in the cavity, fluid gauge pressure, temperature, humidity and chemical concentration or any sub-combination thereof.

[0052] Example 8. A system according to any of the foregoing embodiments, wherein the ultrasonic device and the fluid and lighting environment control device are connected to the computing device to form a sensing-control-feedback unit to maintain a variable environment.

[0053] Example 9. The system according to Example 6, wherein the fluid characteristics and the lighting characteristics are determined and adjusted by the computing device or by the user.

[0054] Example 10. A system according to any of the foregoing embodiments, wherein the structure in fluid communication and illumination communication with the wearable cavity is determined and adjusted by the computing device or by the user.

[0055] Example 11. The system according to Example 10, wherein the structure in fluid and illumination communication with the wearable cavity includes an eyeball, a channel connecting the interior of the eye to the surface of the eye, and a channel on the eyelid for delivering fluid and illumination to the cavity.

[0056] Example 12. A method for altering the properties of the eye, comprising: Vibration is applied through an actuator that contacts the orbital bone via the skin; The cavity is heated to set the temperature to a first temperature for a predetermined period of time until the temperature exceeds a second temperature; Once the set temperature is reached, the vibration cycle is set. After the set temperature is reached and the set vibration cycle is completed, cavity pressure cycling begins. The chamber pressure cycle is completed, and then the heating is completed.

[0057] Example 13. The method according to Example 12, wherein the first temperature is 50°C, the predetermined time is 30 minutes, and the second temperature is 42°C.

[0058] Example 14. The method according to Example 12 or 13, wherein the actuator is configured to vibrate in the range of 0.5 MHz to 4 MHz.

[0059] Example 15. The method according to any of the foregoing embodiments, wherein the vibration is configured to surround the eye socket, thereby enabling the relaxation of appendages and tissues attached to the eye socket.

[0060] Example 16. The method according to any of the foregoing embodiments, wherein the chamber pressure cycle is performed in a range of 500 mmHg to 900 mmHg and for a period of up to 30 minutes.

[0061] Example 17. The method according to any of the foregoing embodiments, wherein the cavity pressure cycle includes a starting cycle, a changing cycle, and an ending cycle.

[0062] Example 18. The method according to Example 17, wherein the initial cycle includes maintaining a pressure cycle in steps of at least 5 mmHg and at most 1 minute to set the pressure for the start of the expansion cycle.

[0063] Example 19. The method according to Example 17 or 18, wherein the alteration cycle comprises maintaining a negative pressure cycle with or without leakage for at least 5 steps with a step size of at least 5 mmHg and a duration of at most 10 minutes.

[0064] Example 20. The method according to any one of Examples 17 to 19, wherein the alternation cycle comprises maintaining a negative pressure and a positive pressure cycle with or without leakage for at least five steps with a step size of at least 5 mmHg and a duration of at most 10 minutes.

[0065] Example 21. The method according to any one of Examples 17 to 20, wherein the termination of the cycle includes maintaining the pressure cycle in steps of at least 5 mmHg and at most 1 minute to set the negative pressure to be 2 mmHg lower than the external pressure.

[0066] Example 22. The method according to any of the foregoing embodiments further includes applying a light beam or light field to the eye, wherein the light beam or light field has a wavelength in the range of 600 nm and 700 nm and a power level in the range of 0.03 mW and 0.06 mW.

[0067] Example 23. The method according to Example 22 further includes controlling the intensity and distribution of the light beam or light field by means of a dynamic light diffuser optionally having a polarizer to achieve desired light intensity and uniformity.

[0068] All patents, patent applications, provisional applications and publications referenced or cited herein are incorporated herein by reference in their entirety (including all figures and tables) to the extent that they are consistent with the express teachings of this specification.

[0069] It should be understood that the examples and embodiments described herein are for illustrative purposes only, and various modifications or variations thereof will occur to those skilled in the art, and such modifications or variations will be included within the spirit and scope of this application and the scope of the appended claims. Furthermore, any element or limitation of any invention or embodiment thereof disclosed herein may be combined with any and / or all other elements or limitations disclosed herein (alone or in any combination) or any other invention or embodiment thereof, and all such combinations are considered within the scope of the invention but are not limited thereto.

Claims

1. A wearable system for altering the properties of the eye, comprising: Ultrasonic equipment; At least one sealed cavity; Fluid and lighting environment control equipment; Controller; One or more feedback sensors; as well as Computing devices.

2. The system according to claim 1, wherein, The fluid and lighting environment control device is configured to control lighting, liquids, or gases.

3. The system according to claim 1, wherein, The ultrasound device is configured to contact the skin around the eye socket.

4. The system according to claim 3, wherein, The ultrasound device is configured to apply ultrasound waves to the eye socket and to the connective tissue connected to the eye socket.

5. The system according to claim 1, wherein, The fluid and lighting environment control device is configured to sense and control at least one fluid characteristic and at least one lighting characteristic.

6. The system according to claim 5, wherein, The fluid characteristic is at least one of the fluid gauge pressure, temperature, humidity, or chemical concentration of the fluid in the cavity.

7. The system according to claim 6, wherein, The controlled fluid characteristics include the fluid gauge pressure, temperature, humidity, and chemical concentration of the fluid in the cavity, or any sub-combination thereof.

8. The system according to claim 1, wherein, The ultrasonic device and the fluid and lighting environment control device are connected to the computing device to form a sensing-control-feedback unit to maintain a variable environment.

9. The system according to claim 6, wherein, The fluid characteristics and the lighting characteristics are determined and adjusted by the computing device or by the user.

10. The system according to claim 1, wherein, The structure connected to the wearable cavity in fluid and lighting communication is determined and adjusted by the computing device or by the user.

11. The system according to claim 10, wherein, The structure in fluid and lighting communication with the wearable cavity includes an eyeball, a channel connecting the interior of the eye to the surface of the eye, and a channel on the eyelid for delivering fluid to the cavity.

12. A method for altering properties of the eye, comprising: Vibration is applied through an actuator that contacts the orbital bone via the skin; The cavity is heated to set the temperature to a first temperature and maintained for a predetermined period of time until the temperature exceeds a second temperature; Once the set temperature is reached, set the vibration cycle. After the set temperature is reached and the set vibration cycle is completed, the cavity pressure cycle begins; The chamber pressure cycle is completed, and then the heating is completed.

13. The method according to claim 12, wherein, The first temperature is 50°C, the predetermined time is 30 minutes, and the second temperature is 42°C.

14. The method according to claim 12, wherein, The actuator is configured to vibrate in the range of 0.5 MHz to 4 MHz.

15. The method according to claim 12, wherein, The vibration is configured to surround the eye socket, thereby relaxing the appendages and tissues attached to the eye socket.

16. The method according to claim 12, wherein, The chamber pressure cycle is performed within a range of 500 mmHg to 900 mmHg and for a period of up to 30 minutes.

17. The method according to claim 12, wherein, The chamber pressure cycle includes a starting cycle, a changing cycle, and an ending cycle.

18. The method according to claim 17, wherein, The initial cycle includes a step-hold pressure cycle with a step size of at least 5 mmHg and a duration of at most 1 minute to set the pressure for initiating the expansion cycle.

19. The method of claim 17, wherein, The alternation cycle includes at least five progressive negative pressure cycles, with or without leakage, with a step size of at least 5 mmHg and a duration of at most 10 minutes.

20. The method of claim 17, wherein, The alternation cycle includes at least five progressive negative and positive pressure cycles, with or without leakage, in steps of at least 5 mmHg and for a duration of up to 10 minutes.

21. The method according to claim 17, wherein, The termination cycle includes a step-by-step pressure maintenance cycle with a step size of at least 5 mmHg and a duration of at most 1 minute, to set the negative pressure to 2 mmHg lower than the external pressure.

22. The method of claim 12, further comprising: A light beam or light field is applied to the eye, wherein the light beam or light field has a wavelength in the range of 600 nm and 700 nm and a power level in the range of 0.03 mW and 0.06 mW.

23. The method of claim 22, further comprising: The intensity and distribution of the light beam or light field can be controlled by a dynamic light diffuser that optionally has a polarizer to achieve the desired light intensity and uniformity.

Images